Carl Feind, MD
Interventional Cardiology · McComb, MSNPI 1033181722
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 456 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,343 and has fallen 79.1% since, to $281 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MS, where the typical reported total is $7,952.
Across 456 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Medtronic$2K
- Novartis$990
- Johnson & Johnson$761
- Boehringer Ingelheim$384
- Abiomed$384
- plus $2K from 26 others
What the payments were for
- Food & beverage$7,689100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 115 | $1,701 |
| Medtronic(2 entities) | 75 | $1,562 |
| Novartis | 81 | $990 |
| Johnson & Johnson | 46 | $761 |
| Boehringer Ingelheim | 22 | $384 |
| Abiomed | 21 | $384 |
| Merck | 19 | $307 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $249 |
| AstraZeneca | 9 | $236 |
| Actelion Pharmaceuticals US, Inc. | 2 | $137 |
| Lundbeck LLC | 1 | $112 |
| Astellas Pharma US Inc | 4 | $89 |
| Amgen | 6 | $89 |
| Pfizer | 6 | $89 |
| E.r. Squibb & Sons, L.L.C. | 5 | $67 |
| Daiichi Sankyo Inc. | 3 | $65 |
| Boston Scientific | 3 | $59 |
| Scpharmaceuticals Inc. | 3 | $52 |
| Lexicon Pharmaceuticals, Inc. | 3 | $49 |
| Sanofi-aventis U.S. LLC | 2 | $48 |
| Impulse Dynamics (USA) Inc. | 2 | $36 |
| Bayer | 2 | $36 |
| Chiesi USA, Inc. | 2 | $33 |
| Philips North America LLC | 2 | $30 |
| Cardiovascular Systems Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| KCI USA, Inc. | 1 | $17 |
| Angiodynamics, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Medela LLC | 1 | $15 |
| Lemaitre Vascular, Inc. | 1 | $14 |
| Kls-martin L.p. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$261
- Fortify Assura$136
- FARXIGA$125
- XARELTO$122
- VYEPTI$112
- Impella$109
How this compares
$7,689 in reported general payments places this provider in the 45th percentile of 65 interventional cardiology providers in Mississippi.
See all interventional cardiology providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 381 | $359,655 |
| EntrestoSacubitril/Valsartan | 228 | $206,356 |
| EliquisApixaban | 205 | $180,270 |
| JardianceEmpagliflozin | 115 | $101,189 |
| FarxigaDapagliflozin Propanediol | 45 | $38,845 |
| BrilintaTicagrelor | 41 | $21,127 |
| Amiodarone Hcl | 344 | $7,212 |
| Ranolazine ErRanolazine | 77 | $6,674 |
| Atorvastatin Calcium | 693 | $6,404 |
| ClopidogrelClopidogrel Bisulfate | 473 | $4,792 |
| Carvedilol | 569 | $3,719 |
| SotalolSotalol Hcl | 197 | $2,525 |
| Allopurinol | 97 | $1,430 |
| Minoxidil | 34 | $1,207 |
| Losartan Potassium | 169 | $1,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $761 | $359,655381 claims |
| NovartisEntresto | $990 | $206,356228 claims |
| PfizerEliquis | $89 | $180,270205 claims |
| Boehringer IngelheimJardiance | $384 | $101,189115 claims |
| AstraZenecaFarxiga, Brilinta | $236 | $59,97286 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 65 interventional cardiology providers in Mississippi.
Other interventional cardiology in McComb
- Christos KasapisMcComb$11K
- Ali HomayuniMcComb$7K
- Alaa OmarMcComb$7K
- John WinscottJackson$482K
- William CrowderJackson$331K
- Foluso FakoredeCleveland$298K
- James BennettJackson$160K
- Abdul BahroFlowood$132K
- Brett BennettJackson$126K
- John KingColumbus$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.